Altrenogest Solution
Loading...Altrenogest Solution Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Keep this and all medication out of the reach of children.
User/Handler Safety: Avoid skin contact. Wear vinyl, neoprene or nitrile protective gloves when handling this product. DO NOT USE LATEX GLOVES
Pregnant women or women who suspect they are pregnant should not handle altrenogest solution 0.22%. Women of childbearing age should exercise extreme caution when handling this product. Accidental absorption could lead to a disruption of the menstrual cycle or prolongation of pregnancy. Wash off accidental spillage on the skin immediately with soap and water.
People who should not handle this product:
1. Women who are or suspect they are pregnant.
2. Anyone with thrombophlebitis or thromboembolic disorders or with a history of these events.
3. Anyone with cerebral-vascular or coronary-artery disease.
4. Women with known or suspected carcinoma of the breast.
5. People with known or suspected estrogendependent neoplasia.
6. Women with undiagnosed vaginal bleeding.
7. People with benign or malignant tumors which developed during the use of oral contraceptives or other estrogen-containing products.
8. Anyone with liver dysfunction or disease.
Accidental exposure: Altrenogest is readily absorbed from contact with the skin. In addition, this oil based product can penetrate porous gloves. Altrenogest should not penetrate intact vinyl, neoprene or nitrile protective gloves; however, if there is leakage (i.e., pinhole, spillage, etc.) the contaminated area covered by such occlusive materials may have increased absorption. DO NOT USE LATEX GLOVES
The following measures are recommended in case of accidental exposure.
Skin Exposure: Wash immediately with soap and water.
Eye Exposure: Immediately flush with plenty of water for 15 minutes. Get medical attention.
If Swallowed:Do not induce vomiting.
Altrenogest solution 0.22% contains an oil. Call a physician. Vomiting should be supervised by a physician because of possible pulmonary damage via aspiration of the oil base. If possible, bring the container and labeling to the physician.
Effects of Overexposure: There has been no human use of this specific product. The information contained in this section is extrapolated from data available on other products of the same pharmacological class that have been used in humans. Effects anticipated are due to the progestational activity of altrenogest. Acute effects after a single exposure are possible; however, continued daily exposure has the potential for more untoward effects such as disruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, prolongation of pregnancy and headaches. The oil base may also cause complications if swallowed. In addition, the list of people who should not handle this product is based upon the known effects of progestins used in humans on a chronic basis.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
There is currently no usage information available for this product. We apologize for any inconvenience.
History
There is currently no drug history available for this drug.
Other Information
Altrenogest Solution
(altrenogest)
SOLUTION 0.22%
(2.2 mg/mL)
FOR ORAL USE IN ANIMALS ONLY
Drug Facts:
Active ingredients: Altrenogest Solution 0.22% (2.2 mg/mL)
Use: For synchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with altrenogest solution 0.22% results in estrus (standing heat) 4 to 9 days after completion of the 14-day treatment period.
Caution: Federal law prohibits extra-label use of this drug to enhance food and/or fiber production in animals.
Do Not Use: In gilts having a previous or current history of uterine inflammation (i.e., acute, subacute or chronic endometritis).
Sources
Altrenogest Solution Manufacturers
-
Ceva Santé Animale
![Altrenogest Solution [Ceva Santé Animale]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Altrenogest Solution | Ceva Santé Animale
Dosage and Directions: While wearing protective gloves, remove shipping cap and seal; replace with enclosed plastic dispensing cap. Remove cover from bottle dispensing tip and connect luer lock syringe (without needle). Draw out appropriate volume of Altrenogest Solution. (Note: Do not remove syringe while bottle is inverted as spillage may result.) Detach syringe and replace cover on bottle dispensing tip to prevent leakage. Administer 6.8 mL (15 mg altrenogest) per gilt once daily for 14 consecutive days. Treat gilts on an individual animal basis by top-dressing Altrenogest Solution on a portion of each gilt’s daily feed allowance. To produce the desired synchronization of estrus in a group of gilts, treat all of the gilts daily for the same 14-day period. Excessive use of a syringe may cause the syringe to stick; therefore, replace syringe as necessary.
Login To Your Free Account